scispace - formally typeset
P

Po-Huang Lee

Researcher at National Taiwan University

Publications -  520
Citations -  15413

Po-Huang Lee is an academic researcher from National Taiwan University. The author has contributed to research in topics: Transplantation & Hepatocellular carcinoma. The author has an hindex of 65, co-authored 511 publications receiving 14174 citations. Previous affiliations of Po-Huang Lee include I-Shou University & University of Pittsburgh.

Papers
More filters
Journal ArticleDOI

Elastic modulus measurements of human liver and correlation with pathology.

TL;DR: Results indicated that the elasticity imaging of the liver may provide significant clinical values if the elastic modulus can be accurately measured, and that severity of fibrosis had a good correlation with stiffness of the Liver.
Journal ArticleDOI

All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies

TL;DR: It is concluded that HLA antibodies may be a prerequisite for chronic immunologic rejection, and 29 consecutive cases of chronic rejection failures as much as one year before the loss of grafts were found.
Journal ArticleDOI

Familial Risk of Hepatocellular Carcinoma Among Chronic Hepatitis B Carriers and Their Relatives

TL;DR: First-degree relatives of patients with HBV-related HCC appear to be at increased risk of HCC and should be considered in the formulation of H CC-screening programs.
Journal ArticleDOI

De novo demonstration and co-localization of free-radical production and apoptosis formation in rat kidney subjected to ischemia/reperfusion.

TL;DR: It is concluded that ROS produced in significant amounts in PT epithelium under ischemia/reperfusion or hypoxia/ reoxygenation conditions may be responsible for the apoptotic death of these cells.
Journal ArticleDOI

Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study.

TL;DR: Percutaneous ethanol injection therapy appears to be as safe and effective as resection, and both treatments can be considered first-line options for small hepatocellular carcinoma.